PMID- 10601354
OWN - NLM
STAT- MEDLINE
DCOM- 20000128
LR  - 20190508
IS  - 0022-1007 (Print)
IS  - 0022-1007 (Linking)
VI  - 190
IP  - 12
DP  - 1999 Dec 20
TI  - A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor
      results from reverse strand transcription.
PG  - 1793-800
AB  - By stimulating blood lymphocytes from a renal cell carcinoma patient in vitro
      with the autologous tumor cells, we obtained cytolytic T lymphocyte (CTL) clones 
      that killed several autologous and allogeneic histocompatibility leukocyte
      antigen (HLA)-B7 renal carcinoma cell lines. We identified the target antigen of 
      these CTLs by screening COS cells transfected with the HLA-B7 cDNA and with a
      cDNA library prepared with RNA from the tumor cells. The antigenic peptide
      recognized by the CTLs has the sequence LPRWPPPQL and is encoded by a new gene,
      which we named RU2. This gene is transcribed in both directions. The antigenic
      peptide is not encoded by the sense transcript, RU2S, which is expressed
      ubiquitously. It is encoded by an antisense transcript, RU2AS, which starts from 
      a cryptic promoter located on the reverse strand of the first intron and ends up 
      on the reverse strand of the RU2S promoter, which contains a polyadenylation
      signal. This mechanism of antigen expression is unprecedented and further
      illustrates the notion that many peptides recognized by T cells cannot be
      predicted from the primary structure of the major product of the encoding gene.
      Antisense transcript RU2AS is expressed in a high proportion of tumors of various
      histological types. It is absent in most normal tissues, but is expressed in
      testis and kidney, and, at lower levels, in urinary bladder and liver. Short-term
      cultures of normal epithelial cells from the renal proximal tubule expressed
      significant levels of RU2AS message and were recognized by the CTLs. Therefore,
      this antigen is not tumor specific, but corresponds to a self-antigen with
      restricted tissue distribution.
FAU - Van Den Eynde, B J
AU  - Van Den Eynde BJ
AD  - Ludwig Institute for Cancer Research, Brussels Branch, B-1200 Brussels, Belgium. 
      vandeneynde@licr.ucl.ac.be
FAU - Gaugler, B
AU  - Gaugler B
FAU - Probst-Kepper, M
AU  - Probst-Kepper M
FAU - Michaux, L
AU  - Michaux L
FAU - Devuyst, O
AU  - Devuyst O
FAU - Lorge, F
AU  - Lorge F
FAU - Weynants, P
AU  - Weynants P
FAU - Boon, T
AU  - Boon T
LA  - eng
SI  - GENBANK/AF181720
SI  - GENBANK/AF181721
SI  - GENBANK/AF181722
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Antigens, Neoplasm)
SB  - IM
CIN - J Exp Med. 1999 Dec 20;190(12):1729-32. PMID: 10601348
MH  - Amino Acid Sequence
MH  - Antigen Presentation/genetics
MH  - Antigens, Neoplasm/*genetics/*immunology
MH  - Base Sequence
MH  - Carcinoma, Renal Cell/genetics/*immunology
MH  - *Cytotoxicity, Immunologic
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kidney Neoplasms/genetics/*immunology
MH  - Molecular Sequence Data
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - *Transcription, Genetic
MH  - Tumor Cells, Cultured
PMC - PMC2195717
EDAT- 1999/12/22 09:00
MHDA- 2000/04/25 09:00
CRDT- 1999/12/22 09:00
PHST- 1999/12/22 09:00 [pubmed]
PHST- 2000/04/25 09:00 [medline]
PHST- 1999/12/22 09:00 [entrez]
AID - 10.1084/jem.190.12.1793 [doi]
PST - ppublish
SO  - J Exp Med. 1999 Dec 20;190(12):1793-800. doi: 10.1084/jem.190.12.1793.